Why the study?
To assess the effect of thrombolytic therapy compared to classic therapy on clinical prognostic markers and evaluate associated bleeding risk in intermediate-high risk pulmonary embolism.
Does thrombolytic therapy reduce early mortality and hemodynamic instability in patients with intermediate-high risk pulmonary embolism?
Cohort (n=82)
No
Does thrombolytic therapy reduce early mortality and hemodynamic instability in patients with intermediate-high risk pulmonary embolism?
In a cohort of patients with intermediate-high risk pulmonary embolism, thrombolytic therapy was associated with reduced early mortality and hemodynamic instability compared to anticoagulation alone, though treatment assignment was confounded by baseline bleeding risk.
Answers are grounded in this paper and cite their sources.
Should not change practice in intermediate-high risk PE due to confounding by bleeding risk; leaves open need for randomized confirmation.
The objective of the study is to assess the efect of thrombolitic therapy on clinical prognostic markers in patients with intermediate-high risk pulmonary embolism compared to clasic therapy, and also the assessment of the bleeding risk associated with thrombolitic therapy. Material and methods. We included 82 consecutive patients with intermediate-high risk pulmonary embolism, which were divided in two groups: study group (thrombolysed) and control group (treated with unfractioned heparine alone). Patients with lower bleeding risk were included in control group. Patients were assessed regarding the right ventricle dysfunction markers (both imagistic and biochemical) on admision and on 48 h. The early (7th day) mortality rate and hemodinamic instability rate were evaluated in the two groups, also the major bleeding rate. Outcomes. We proved a statistical significant lower mortality rate in the study group, with no difference regarding the major bleedings. Meanwhile, the hemodinamic instability was lower in the study group compared to control group. Conclusions. The proper patient selection with intermediate-high pulmonary embolism for thrombolitic therapy can bring important benefits in terms of mortality and bleeding complications.
No takes yet. Share an insight, caveat, or question.
Ion et al. (2020) conducted a cohort in Intermediate-high risk pulmonary embolism (n=82). Thrombolytic therapy (alteplase/t-PA) vs. Unfractionated heparin alone was evaluated on Early mortality rate at 7 days (p=0.04).
Synapse has enriched 10 related papers. Consider them for comparative context: